Latest Headlines

  1. Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI As A Separate Company To Commercialize And Expand Its Multi-Agent AI Co-Scientist Platform For The Transformation Of Medicine 8/3/2026

    Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma.

  2. Lupin Announces The Approval Of Diazepam Injection, USP In The United States 7/31/2026

    Global pharma major Lupin Limited (Lupin) today announced that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes.

  3. Henlius Announces IND Approval For Its Innovative PD-L1 ADC HLX43 In Combination With Bevacizumab ± Chemotherapy 7/31/2026

    Henlius today announced that the investigational new drug (IND) application for HLX43, the company’s innovative programmed death-ligand 1 (PD-L1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab with or without chemotherapy, for the treatment of advanced/metastatic solid tumors has been approved by China’s National Medical Products Administration (NMPA).

  4. HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation For AI-Designed Candidates 7/30/2026

    HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The program supports AI drug-discovery teams in translating AI-generated targets, molecules and mechanism hypotheses into in vivo pharmacology, mechanism, PK/PD, biomarker and pre-IND translational evidence in autoimmune and allergy disease models.

  5. Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Sasineprocel (ANPD001) To Treat Parkinson's Disease 7/30/2026

    Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson's Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA).

  6. Sail Biomedicines Announces Strategic Collaboration To Develop New Class Of Medicines For In Vivo CAR-T 7/29/2026

    Sail Biomedicines, a Flagship Pioneering company creating a new class of RNA medicines, today announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies that have the potential to improve patient outcomes for immune-mediated diseases.

  7. Ono Pharmaceutical Partners With Phylo To Embed Agentic AI With Every Discovery Scientist 7/28/2026

    Ono Pharmaceutical Co., Ltd. (TYO: 4528, "Ono") and Phylo, Inc. ("Phylo") today announced a collaboration that brings Biomni Lab, Phylo's agentic AI platform for biomedical research, to Ono's drug discovery scientists.

  8. Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate For Drug Discovery Campaign 7/28/2026

    Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has narrowed its focus from the broader pool of SLC transport protein candidates previously identified through its structural analysis efforts, selecting a candidate for a drug discovery campaign.

  9. HAYA Therapeutics Receives FDA Fast Track Designation For HTX-001 7/28/2026

    HAYA Therapeutics SA, a clinical-stage biotechnology company pioneering precision RNA-guided therapeutics that target the regulatory genome to reprogram disease-driving cell states in common, chronic and age-related diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).

  10. Enveric Biosciences Welcomes Final FDA Guidance For Psychedelic Drug Development 7/28/2026

    Enveric Biosciences (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.